This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/7579422.stm

The article has changed 6 times. There is an RSS feed of changes available.

Version 0 Version 1
Experts in drug 'ration' warning Experts in drug 'ration' warning
(about 3 hours later)
Some of the UK's top cancer consultants warn that NHS drug 'rationing' is forcing patients to remortgage their homes to pay for treatment. Some of the UK's top cancer consultants warn that NHS drug "rationing" is forcing patients to remortgage their homes to pay for treatment.
The specialists accuse the government drugs advisory body of 'rationing' too severely and call for a "radical change" in the way decisions are made. The specialists accuse the government drugs advisory body of "rationing" too severely and call for a "radical change" in the way decisions are made.
Their letter to the Sunday Times also says research success is not being translated into modern treatments.Their letter to the Sunday Times also says research success is not being translated into modern treatments.
It follows a decision not to offer some drugs to NHS kidney cancer patients.It follows a decision not to offer some drugs to NHS kidney cancer patients.
Earlier this month, the National Institute of Health and Clinical Excellence (NICE) published its draft guidelines on treatments for patients with advanced kidney cancer.Earlier this month, the National Institute of Health and Clinical Excellence (NICE) published its draft guidelines on treatments for patients with advanced kidney cancer.
We have seen distraught patients remortgaging their houses, giving up pensions and selling cars to buy drugs Letter signed by 26 consultantsWe have seen distraught patients remortgaging their houses, giving up pensions and selling cars to buy drugs Letter signed by 26 consultants
It concluded that the drugs - bevacizumab, sorafenib, sunitinib and temsirolimus - did not offer value for money.It concluded that the drugs - bevacizumab, sorafenib, sunitinib and temsirolimus - did not offer value for money.
But in their letter, the 26 cancer specialists say the decision shows how "poorly" NICE assesses new cancer treatments.But in their letter, the 26 cancer specialists say the decision shows how "poorly" NICE assesses new cancer treatments.
"Its economic formulas are simply not suitable for addressing cost-effectiveness in this area of medicine," they write."Its economic formulas are simply not suitable for addressing cost-effectiveness in this area of medicine," they write.
They continue: "It is essential that NICE gets its sums right. We have seen distraught patients remortgaging their houses, giving up pensions and selling cars to buy drugs that are freely available to those using health services in countries of comparable wealth."They continue: "It is essential that NICE gets its sums right. We have seen distraught patients remortgaging their houses, giving up pensions and selling cars to buy drugs that are freely available to those using health services in countries of comparable wealth."
'Change needed''Change needed'
The consultants, who include the directors of oncology at Britain's two biggest cancer hospitals, the Royal Marsden in London and Christie Hospital in Manchester, say it is not right the NHS cannot find the money for the drugs.The consultants, who include the directors of oncology at Britain's two biggest cancer hospitals, the Royal Marsden in London and Christie Hospital in Manchester, say it is not right the NHS cannot find the money for the drugs.
"We now spend similar amounts to Europe on health generally and cancer care in particular, but less than two thirds of the European average on cancer drugs."We now spend similar amounts to Europe on health generally and cancer care in particular, but less than two thirds of the European average on cancer drugs.
"It just can't be that everybody else around the world is wrong about access to innovative cancer care and the NHS right in rationing it so severely.""It just can't be that everybody else around the world is wrong about access to innovative cancer care and the NHS right in rationing it so severely."
There is a finite pot of money for the NHS, which is determined annually by parliament National Institute of Health and Clinical ExcellenceThere is a finite pot of money for the NHS, which is determined annually by parliament National Institute of Health and Clinical Excellence
While Britain is a leading contributor to cancer research, this is not translated into "modern treatment for all our patients," they say.While Britain is a leading contributor to cancer research, this is not translated into "modern treatment for all our patients," they say.
They add: "The time has come for a radical change in how the NHS makes rationing decisions for cancer."They add: "The time has come for a radical change in how the NHS makes rationing decisions for cancer."
Professor Peter Johnson, from Cancer Research UK, earlier this month also said NICE's decision raised "questions" about whether its system of appraisal was appropriate for all types of drugs.Professor Peter Johnson, from Cancer Research UK, earlier this month also said NICE's decision raised "questions" about whether its system of appraisal was appropriate for all types of drugs.
Andrew Dillon, the NICE chief executive, and Sir Michael Rawlins, NICE's chairman, told the Sunday Times the NHS did not have unlimited funds to provide all available treatments.Andrew Dillon, the NICE chief executive, and Sir Michael Rawlins, NICE's chairman, told the Sunday Times the NHS did not have unlimited funds to provide all available treatments.
"There is a finite pot of money for the NHS, which is determined annually by parliament," they said."There is a finite pot of money for the NHS, which is determined annually by parliament," they said.
"If one group of patients is provided with cost-ineffective care, other groups - lacking powerful lobbyists - will be denied cost-effective care for miserable conditions like schizophrenia, Crohn's disease or cystic fibrosis.""If one group of patients is provided with cost-ineffective care, other groups - lacking powerful lobbyists - will be denied cost-effective care for miserable conditions like schizophrenia, Crohn's disease or cystic fibrosis."
More than 7,000 people are diagnosed with kidney cancer annually in the UK.More than 7,000 people are diagnosed with kidney cancer annually in the UK.
Of these, around 1,700 patients will be diagnosed with advanced kidney cancer.Of these, around 1,700 patients will be diagnosed with advanced kidney cancer.
Although none of the available treatments "cure" cancer that has spread from the initial tumour, they can help extend a patients' life by around five to six months.Although none of the available treatments "cure" cancer that has spread from the initial tumour, they can help extend a patients' life by around five to six months.